D. Boral Capital Reaffirms “Buy” Rating for VolitionRx (NYSE:VNRX)

VolitionRx (NYSE:VNRX)‘s stock had its “buy” rating reissued by analysts at D. Boral Capital in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $5.00 price target on the stock.

A number of other analysts have also recently issued reports on the company. Maxim Group cut VolitionRx from a “buy” rating to a “hold” rating in a research note on Wednesday. HC Wainwright cut their price target on VolitionRx from $2.50 to $1.50 and set a “buy” rating for the company in a report on Monday, November 17th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $3.17.

VolitionRx Stock Up 7.2%

NYSE:VNRX traded up $0.02 during trading hours on Thursday, hitting $0.31. 1,932,244 shares of the stock were exchanged, compared to its average volume of 489,188. The company’s 50 day moving average is $0.44 and its two-hundred day moving average is $0.58. The company has a market capitalization of $37.45 million, a P/E ratio of -0.85 and a beta of 1.24. VolitionRx has a twelve month low of $0.27 and a twelve month high of $0.94.

Insider Buying and Selling

In related news, CEO Cameron John Reynolds bought 110,000 shares of VolitionRx stock in a transaction that occurred on Tuesday, October 14th. The shares were acquired at an average cost of $0.51 per share, for a total transaction of $56,100.00. Following the completion of the acquisition, the chief executive officer directly owned 2,534,847 shares of the company’s stock, valued at approximately $1,292,771.97. The trade was a 4.54% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Guy Archibald Innes purchased 96,153 shares of the firm’s stock in a transaction on Tuesday, October 14th. The shares were acquired at an average price of $0.51 per share, with a total value of $49,038.03. Following the completion of the acquisition, the director owned 1,062,967 shares in the company, valued at approximately $542,113.17. This trade represents a 9.95% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired 289,229 shares of company stock worth $146,557 in the last 90 days. Company insiders own 10.40% of the company’s stock.

Institutional Trading of VolitionRx

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Armistice Capital LLC boosted its stake in shares of VolitionRx by 10.4% in the 3rd quarter. Armistice Capital LLC now owns 9,380,425 shares of the company’s stock worth $6,367,000 after buying an additional 887,351 shares during the last quarter. Lagoda Investment Management L.P. boosted its position in VolitionRx by 6.7% in the third quarter. Lagoda Investment Management L.P. now owns 12,487,000 shares of the company’s stock worth $8,476,000 after purchasing an additional 782,000 shares during the last quarter. Citadel Advisors LLC increased its position in shares of VolitionRx by 70.1% during the 3rd quarter. Citadel Advisors LLC now owns 329,520 shares of the company’s stock valued at $224,000 after purchasing an additional 135,775 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of VolitionRx in the 3rd quarter worth about $28,000. Finally, Silverberg Bernstein Capital Management LLC increased its holdings in VolitionRx by 15.6% during the third quarter. Silverberg Bernstein Capital Management LLC now owns 232,082 shares of the company’s stock worth $157,000 after buying an additional 31,300 shares during the last quarter. 8.09% of the stock is owned by institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.